Improving outcomes for patients with liver cancer
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
['FUNDING_OTHER'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10687031
This study is looking for better ways to catch and treat liver cancer early, especially for those at higher risk, so that patients can have better outcomes and live longer, and it may involve patients trying out new treatments and tests.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10687031 on ClinicalTrials.gov |
What this research studies
This research focuses on hepatocellular carcinoma (HCC), a type of liver cancer that has seen rising incidence and mortality rates. The project aims to enhance early intervention strategies to improve patient outcomes and reduce death rates associated with HCC. By analyzing patient data and developing new treatment approaches, the research seeks to address the increasing burden of this disease, particularly in high-risk populations. Patients may be involved in clinical trials that test innovative therapies and diagnostic methods.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with hepatocellular carcinoma, particularly those in high-incidence areas such as Texas.
Not a fit: Patients with other types of cancer or those without a diagnosis of hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better quality of life for patients with liver cancer.
How similar studies have performed: Previous research has shown promising results in improving outcomes for liver cancer patients through early intervention strategies.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERETTA, LAURA — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: BERETTA, LAURA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer